Spotlight On... Shire finally gets Baxalta to the deal-talks table; NICE backs Novartis' Entresto in some heart failure patients; Sanofi's Praluent wins top billing on UnitedHealth formulary; and more...

Shire CEO Flemming Ornskov

Shire ($SHPG) is reportedly one step closer to achieving its dream of nabbing Baxalta ($BXLT) to become a global rare-disease leader. The two companies are in takeover talks, Bloomberg reported Friday, with the Illinois pharma looking for a sweetened bid with a cash component. The way Shire sees it, a combined company could generate $20 billion in sales by 2020, with as many as 30 new drugs rolling out over the next 5 years, CEO Flemming Ornskov has said. More from FiercePharma

> The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended NHS use of Novartis' ($NVS) Entresto for a subset of heart failure patients whose hearts are particularly poor at pumping blood. Release

> U.K. cost watchdogs have also endorsed prostate cancer med Xtandi from Astellas in pre-chemo patients, but they denied Johnson & Johnson's ($JNJ) rival med, Zytiga, in the same population. Story

> Sanofi ($SNY) and Regeneron's ($REGN) Praluent will be UnitedHealth Group's ($UNH) preferred PCSK9 drug for treating superhigh LDL cholesterol. Story

> Novo Nordisk ($NVO) has submitted an NDA to the FDA for faster-acting insulin aspart. Report

> Horizon Pharma ($HZNP) has agreed to buy Crealta Holdings for $510 million in cash, gaining access to gout drug Krystexxa. More

> Alnylam ($ALNY) is planning final trials for ALN-CC5--a paroxysmal nocturnal hemoglobinuria candidate that would compete with Alexion's ($ALXN) pricey Soliris--for 2017. Report

And Finally... Dog owners are wondering whether to vaccinate their dogs against canine influenza virus H3N. More (sub. req.)

Suggested Articles

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.